Within the IBD patients’ group, 57 were treated with anti-TNFα agents (anti-TNFα group), while 94 were treated with any other medical treatment or no medical treatment at all (non-anti-TNFα group) (Figure 1B). This evidence concerns the gene TNF and inflammatory bowel disease.